The Possible Relationship and Drug Targets of Ischemic Stroke and Dementia in Oxidative Stress

  • Miaomiao Zhang
Keywords: Ischemic Stroke; Dementia; The Reactive Oxygen Species

Abstract

There are multiple mechanisms of pathogenic factors in dementia and ischemic-reperfusion injury, such as oxidative stress (OS) and the reactive oxygen species (ROS). NADPH oxidases (NOXs) have a broad distribution in brain and participate in the oxidative stress and inflammatory responses. It may be efficient to treat this specific target of NOX to establish a balance between reactive oxygen species and antioxidants. This review will elaborate the possible relationship and mechanism between the occurrence of stroke and its complications and focus on NOXs, ROS and inflammatory responses to figure out the possible signaling pathway in the perspective of oxidative stress. And NOX2 will be focused to demonstrate the relationship between ischemia-reperfusion and pathogenic factors of dementia via the NOX2/ROS signaling pathway. And considering the upstream and downstream elements and the end results of this signaling pathway, inhibiting NOX2 activity can reduce oxidative damage and inflammatory responses, NOX2 can be considered as a drug target to treat stroke development to reduce the risk of severe dementia.

References

Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta. 2016; 1862(5): 915-25.

Mijajlovic MD, et al. Post-stroke dementia - a comprehensive review. BMC Med. 2017; 15(1): 11.

Huang YY, Chen SD, Leng XY, Kuo K, Wang ZT, Cui M, et al. Post-Stroke Cognitive Impairment: Epidemiology, Risk Factors, and Management. J Alzheimers Dis. 2022; 86(3): 983-99.

Gottesman RF, et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 2014; 71(10): 1218- 27.

Iadecola C, Gottesman RF. Neurovascular and Cognitive Dysfunction in Hypertension. Circ Res. 2019; 124(7): 1025-44.

Sarniak A, Lipinska J, Tytman K, Lipinska S. Endogenous mechanisms of reactive oxygen species (ROS) generation. Postepy Hig Med Dosw (Online). 2016;70(0):1150-65.

Briyal S, Ranjan AK, Gulati A. Oxidative stress: A target to treat Alzheimer's disease and stroke. Neurochem Int. 2023;165:105509.

Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive Oxygen Species in Metabolic and Inflammatory Signaling. Circ Res. 2018;122(6):877-902.

Dominguez C, Delgado P, Vilches A, Martin-Gallan P, Ribo M, Santamarina E, et al. Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke. 2010; 41(4): 653-60.

Cojocaru IM, Cojocaru M, Sapira V, Ionescu A. Evaluation of oxidative stress in patients with acute ischemic stroke. Rom J Intern Med. 2013;51(2):97-106.

Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol. 2010;8(9).

Yang G, et al. Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke. 1994;25(1):165-70.

Barua S, Kim JY, Yenari MA, Lee JE. The role of NOX inhibitors in neurodegenerative diseases. IBRO Rep. 2019;7:59-69.

Anrather J, Racchumi G, Iadecola C. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem. 2006;281(9):5657-67.

Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab. 1999;19(8):819-34.

Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391-7.

Choi DH, Lee J. A Mini-Review of the NADPH oxidases in Vascular Dementia: Correlation with NOXs and Risk Factors for VaD. Int J Mol Sci. 2017;18(11).

Bennett S, Grant MM, Aldred S. Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. J Alzheimers Dis. 2009;17(2):245-57.

Reiss AB, Arain HA, Stecker MM, Siegart NM, Kasselman LJ. Amyloid toxicity in Alzheimer's disease. Rev Neurosci. 2018;29(6):613-27.

Tonnies E, Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease. J Alzheimers Dis. 2017;57(4):1105-21.

Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405.

Hwang S, Kim JK. Effects of NADPH Oxidase Inhibitors and Mitochondria-Targeted Antioxidants on Amyloid beta(1-42)-Induced Neuronal Deaths in Mouse Mixed Cortical Cultures. Chonnam Med J. 2018;54(3):159-66.

Russo R, et al. Motor coordination and synaptic plasticity deficits are associated with increased cerebellar activity of NADPH oxidase, CAMKII, and PKC at preplaque stage in the TgCRND8 mouse model of Alzheimer's disease. Neurobiol Aging. 2018;68:123-33.

Wyssenbach A, Quintela T, Llavero F, Zugaza JL, Matute C, Alberdi E. Amyloid beta-induced astrogliosis is mediated by beta1-integrin via NADPH oxidase 2 in Alzheimer's disease. Aging Cell. 2016;15(6):1140-52.

Hou L, Zhang L, Hong JS, Zhang D, Zhao J, Wang Q. Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Neurodegenerative Diseases: Mechanisms and Therapy. Antioxid Redox Signal. 2020;33(5):374-93.

Chen Z, Tao S, Li X, Zeng X, Zhang M, Yao Q. Anagliptin protects neuronal cells against endogenous amyloid beta (Abeta)-induced cytotoxicity and apoptosis. Artif Cells Nanomed Biotechnol. 2019;47(1):2213-20.

Sorce S, et al. The Role of the NADPH Oxidase NOX2 in Prion Pathogenesis. Plos Pathog. 2014;10(12).

Seredenina T, et al. Evaluation of NADPH oxidases as drug targets in a mouse model of familial amyotrophic lateral sclerosis. Free Radical Bio Med. 2016;97:95-108.

Published
2023-09-15
Section
Original Research Article